UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 6-K
________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2022
Commission File Number: 001-38281

ERYTECH Pharma S.A.
(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 Form 20-F S             Form 40-F £  
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   £  
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   £  














INCORPORATION BY REFERENCE
This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-248953 and 333-259690) and registration statements on Form S-8 (File Nos. 333-222673, 333-232670, 333-239429, 333-255900 and 333-265927), of ERYTECH Pharma S.A. (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.





























INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press Release
On 21 November 2022, ERYTECH Pharma S.A. issued a press release to provide a business and financial update for the third quarter of 2022.

A copy of this press release is attached to this Form 6-K as Exhibit 99.1.













EXHIBITS
ExhibitDescription
99.1
Press Release dated November 21, 2022.

















SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ERYTECH Pharma S.A.
Date:
November 22, 2022
By:
/s/ Eric Soyer
Name Eric Soyer
Title: Chief Financial Officer and Chief Operating Officer

Erytech Pharma (NASDAQ:ERYP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Erytech Pharma Charts.
Erytech Pharma (NASDAQ:ERYP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Erytech Pharma Charts.